Literature DB >> 1124750

Inhibition of gastric acid secretion by metiamide in Zollinger-Ellison syndrome.

M Mainardi, V Maxwell, R A Sturdevant, J I Isenberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1124750     DOI: 10.1007/bf01070731

Source DB:  PubMed          Journal:  Am J Dig Dis        ISSN: 0002-9211


× No keyword cloud information.
  6 in total

Review 1.  Zollinger-Ellison syndrome.

Authors:  J I Isenberg; J H Walsh; M I Grossman
Journal:  Gastroenterology       Date:  1973-07       Impact factor: 22.682

2.  Definition and antagonism of histamine H 2 -receptors.

Authors:  J W Black; W A Duncan; C J Durant; C R Ganellin; E M Parsons
Journal:  Nature       Date:  1972-04-21       Impact factor: 49.962

3.  Inhibition of nocturnal acid secretion in duodenal ulcer by one oral dose of metiamide.

Authors:  G J Milton-Thompson; J G Williams; D J Jenkins; J J Misiewicz
Journal:  Lancet       Date:  1974-04-20       Impact factor: 79.321

4.  Effects in man of histamine H 2 -receptor blockade by burimamide.

Authors:  J H Wyllie; T Hesselbo; J W Black
Journal:  Lancet       Date:  1972-11-25       Impact factor: 79.321

5.  Inhibition of gastric secretion in man by metiamide: a new, orally active histamine H 2 -receptor antagonist.

Authors:  J H Wyllie; W D Ealding; T Hesselbo; J W Plack
Journal:  Gut       Date:  1973-05       Impact factor: 23.059

6.  Metiamide, an H2-receptor blocker, as inhibitor of basal and meal-stimulated gastric acid secretion in patients with duodenal ulcer.

Authors:  M Mainardi; V Maxwell; R A Sturdevant; J I Isenberg
Journal:  N Engl J Med       Date:  1974-08-22       Impact factor: 91.245

  6 in total
  2 in total

Review 1.  Antihistamines: pharmacology and clinical use.

Authors:  D S Pearlman
Journal:  Drugs       Date:  1976       Impact factor: 9.546

2.  Results of surgical management in 92 consecutive patients with Zollinger-Ellison syndrome.

Authors:  S Bonfils; J H Landor; M Mignon; P Hervoir
Journal:  Ann Surg       Date:  1981-12       Impact factor: 12.969

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.